Altogether our findings suggest that bortezomib mediated downregulation of SKP2 is a novel effect in CML cells and implicates that proteasome inhibitors may have a novel therapeutic potential for the intervention of CML. This evidence concerns the gene SKP2 and chronic myelogenous leukemia, BCR-ABL1 positive.